Wei, Fn., Chen, Zl., Yang, Hf. et al. Effect of Sanqi Oral Liquid (三芪口服液) on the expressions of CD4+, CD8+ and CD68+ cells in 5/6 nephrectomized rats with chronic renal failure., Chin. J. Integr. Med. 19, 589–595 (2013). https://doi.org/10.1007/s11655-012-1233-5
Fang-ning Wei, Zi-lin Chen, Hai-feng Yang, et al. Effect of Sanqi Oral Liquid (三芪口服液) on the expressions of CD4+, CD8+ and CD68+ cells in 5/6 nephrectomized rats with chronic renal failure[J]. Chinese Journal of Integrative Medicine, 2013,19(8):589-595.
Wei, Fn., Chen, Zl., Yang, Hf. et al. Effect of Sanqi Oral Liquid (三芪口服液) on the expressions of CD4+, CD8+ and CD68+ cells in 5/6 nephrectomized rats with chronic renal failure., Chin. J. Integr. Med. 19, 589–595 (2013). https://doi.org/10.1007/s11655-012-1233-5DOI:
Fang-ning Wei, Zi-lin Chen, Hai-feng Yang, et al. Effect of Sanqi Oral Liquid (三芪口服液) on the expressions of CD4+, CD8+ and CD68+ cells in 5/6 nephrectomized rats with chronic renal failure[J]. Chinese Journal of Integrative Medicine, 2013,19(8):589-595. DOI: 10.1007/s11655-012-1233-5.
Effect of Sanqi Oral Liquid (三芪口服液) on the expressions of CD4+, CD8+ and CD68+ cells in 5/6 nephrectomized rats with chronic renal failure
摘要
To explore the mechanisms of Chinese herbal medicine Sanqi Oral Liquid (三芪口服液)
composed of Astragalus membranaceus and Panpax notoginseng
in alleviating renal injury by observing its effect on the expressions of CD4+
CD8+ and CD68+ cells in 5/6 nephrectomized rats with chronic renal failure. A total of 102 SD rats were randomly divided into six groups: three treatment groups were administrated with high
medium and low dosage of Sanqi Oral Liquid respectively by gavage; a normal group
a 5/6 nephrectomized model group
and a group treated with coated aldehyde oxygenstarch were used as controls. Following oral administration of Sanqi Oral Liquid for 12 weeks
the general condition and renal pathological changes were observed
and the renal function
platelet count (PLT) and the expressions of CD4+
CD8+ and CD68+ cells were determined for each group. There were proliferation of mesangial matrix
renaltubularnecrosis and obvious tubulointerstitial fibrosis in the model group
and they were much milder in the treatment groups. Compared with the model group
the amounts of blood urea nitrogen (BUN)
serum creatinine (Scr) and PLT in the treatment groups decreased (P<0.05 for all); and in the group administrated of medium dosage of Sanqi Oral Liquid
the expression of CD4+ cells was up-regulated and those of CD8+ and CD68+ cells were down-regulated (P<0.05 for all)
leading to an increased ratio of CD4+/CD8+(P<0.01). Sanqi Oral Liquid has a significant effect on regulating lymphocyte subsets
reducing the infiltration of macrophages in renal tissues and alleviating tubulointerstitial fibrosis
and this may be one of mechanisms of Sanqi Oral Liquid in delaying the progression of chronic kidney diseases.
Abstract
To explore the mechanisms of Chinese herbal medicine Sanqi Oral Liquid (三芪口服液)
composed of Astragalus membranaceus and Panpax notoginseng
in alleviating renal injury by observing its effect on the expressions of CD4+
CD8+ and CD68+ cells in 5/6 nephrectomized rats with chronic renal failure. A total of 102 SD rats were randomly divided into six groups: three treatment groups were administrated with high
medium and low dosage of Sanqi Oral Liquid respectively by gavage; a normal group
a 5/6 nephrectomized model group
and a group treated with coated aldehyde oxygenstarch were used as controls. Following oral administration of Sanqi Oral Liquid for 12 weeks
the general condition and renal pathological changes were observed
and the renal function
platelet count (PLT) and the expressions of CD4+
CD8+ and CD68+ cells were determined for each group. There were proliferation of mesangial matrix
renaltubularnecrosis and obvious tubulointerstitial fibrosis in the model group
and they were much milder in the treatment groups. Compared with the model group
the amounts of blood urea nitrogen (BUN)
serum creatinine (Scr) and PLT in the treatment groups decreased (P<0.05 for all); and in the group administrated of medium dosage of Sanqi Oral Liquid
the expression of CD4+ cells was up-regulated and those of CD8+ and CD68+ cells were down-regulated (P<0.05 for all)
leading to an increased ratio of CD4+/CD8+(P<0.01). Sanqi Oral Liquid has a significant effect on regulating lymphocyte subsets
reducing the infiltration of macrophages in renal tissues and alleviating tubulointerstitial fibrosis
and this may be one of mechanisms of Sanqi Oral Liquid in delaying the progression of chronic kidney diseases.
Norman JT, Fine LG. Progressive renal disease: fibroblasts, extracellular matrix and integrins. Exp Nephrol 1999;7:167–177.
Yang NZ, Zhong D, Zhao DX, Liu PM, Liu XS. Effects of Tongmai Oral Solution on cell proliferation and interleukin- β 1, interleukin-10 production in mesangial cells. Chin J Integr Tradit West Nephrol (Chin) 2007;8:444–447.
Zhao DX, Yang NZ, Zhong D, Liu PM. Effects of Tongmai Oral Solution with compatibility of different proportions for main drug on mesangial cell profliferation. Chin J Integr Tradit West Nephrol (Chin) 2009;10:533–534.
Sha CH, Fu P, Zhou L, Tang WX, Liu F, Li J. Experimental study on animal model for chronic renal failure in rats. Sichuan J Zool (Chin) 2006;25:632–634.
Xu SY, Bian RL, Chen X, eds. Methodology of pharmacology experiment. Beijing: People’s Medical Publishing House; 2003:202–203.
Churg J, Sobin LH. Renal disease: classifycation and atlas of glomerular disease. Tokyo: Lgaku-Shoin;1982:125–128.
Tucci M, Lombardi L, Richards HB, Dammacco F, Silvestris F. Over expression of interleukin-12 and T helper 1 predominance in lupus nephritis. Clin Exp Immunol 2008;154:247–254.
Liang B, Gardner DB, Griswold DE, Bugelski PJ, Song XY. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 2006;119:296–305.
Heymann F, Meyer-Schwesinger C, Hamilton-Williams EE, Hammerich L, Panzer U, Kaden S, et al. Kidney dendritic cell activation is required for progression of renal disease in a mouse model of glomerular injury. J Clin Invest 2009;119:1286–1297.
Vielhauer V, Kulkarni O, Reichel CA, Anders HJ. Targeting the recruitment of monocytes and macrophages in renal disease. Semin Nephrol 2010;30:318–323.
Kuroiwa T, Schlimgen R, Illei GG, McInnes IB, Boumpas DT. Distinct T cell/renaltubular epithelial cell interactions define differential chemokine production: implications for tubulointerstitial injury in chronic glomerulonephritides. J Immunol 2000;164:3323–3329.
Kinsey GR, Huang L, Vergis AL, Li L, Okusa MD. Regulatory T cells contribute to the protective effect of ischemic preconditioning in the kidney. Kidney Int 2010;77:771–780.
Lim DG, Koo SK, Park YH, Kim Y, Kim HM, Park CS, et al. Impact of immunosup-pressants on the therapeutic efficacy of in vitro-expanded CD4+CD25+Foxp3+ regulatory T cells in allotransplantation. Transplantation 2010;89:928–936.
Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, et al. Galectin-3 expression and secretion links macrophage to the promotion of renal fibrosis. Am J Pathol 2008;172:288–298.
Podjarny E, Bernheim J, Hasdan G, Karsh D, Rashid G, Green J, et al. Additive renoprotective effect of candesartan and tetrahydrobiopterin in rats after 5/6 nephrectomy. Nephrol Dial Transplant 2007;22:1864–1872.
Schaier M, Vorwalder S, Sommerer C, Dikow R, Hug F, Gross ML. Role of FTY720 on M1 and M2 macrophages, lymphocytes, and chemokines in 5/6 nephrectomized rats. Am J Physiol Renal Physiol 2009;297:F769–F780.
Yoon JW, Jun HS, Santamaria P. Cellular and molecular mechanisms for the initiation and progression of beta cell destruction resulting from the collaboration between macrophages and T cells. Autoimmunity 1998;27:109–122.
Dunne PJ, Fletcher JM. Recent advances in regulatory T cell therapy of autoimmunity, graft rejection and cancer. Recent Pat Inflamm Allergy Drug Discov 2010;4:231–243.
Xiang J, Huang H, Liu Y. A new dynamic model of CD8+ T effector cell responses via CD4+ T helper-antigenpresenting cells. J Immunol 2005;174:7497–7505.
Saxena V, Lienesch DW, Zhou M, Bommireddy R, Azhar M, Doetschman T, et al. Dual roles of immunoregulatory cytokine TGF-β in the pathogenesis of autoimmunitymediated organ damage. J Immunol 2008;180:1903–1912.
Yokoi H, Sugawara A, Mukoyama M, Mori K, Makino H, Suganami T, et al. Role of connective tissue growth factor in profibrotic action of transforming growth factorbeta: a potential target for preventing renal fibrosis. Am J Kidney Dis 2001;38:S134–138.
Li FL, Yuan JL, Song JX, Shen Y, Liu H, Zhang JL. Study of notoginsenoside on the regulation of peripheral T lymphocytes subsets and costimulation molecules CD2 and CD58 in chronic renal failure. Yunnan J Tradit Chin Med Mater Med (Chin) 2004;25:32–33.
Peng XJ, Wu XC, Zhang GZ, Yi ZW, Zheng WM, He XJ, et al. Regulatory effect of Astragalus membranaceus on the immune disorder in rats with IgA nephropathy. China J Pediatr (Chin) 2008;46:55–60.
Qu LL, Su YL, Li CX, Hou GH. Astragalus membranaceus injection delayed allograft survival related with CD4+ CD25+ regulatory T cells. Transplant Proc 2010;42:3793–3797.
Lee EJ, Ko E, Lee J, Rho S, Ko S, Shin MK, et al. Ginsenoside Rg1 enhances CD4+ T-cell activities and modulates Th1/Th2 differentiation. Int Immunopharmacol 2004;4:235–244.
Management of chronic kidney disease in china calls for the implementation of expert patient program with traditional Chinese medical interventions
Inhibition of the tubular epithelial-to-mesenchymal transition in vivo and in vitro by the Uremic Clearance Granule (尿毒清颗粒)
Longer overall survival in a patient with advanced non-small cell lung cancer treated with Chinese medicine and chemotherapy
Effects of Astragalus membranaceus in promoting T-helper cell type 1 polarization and interferon-γ production by up-regulating T-bet expression in patients with asthma
Study on diagnosis and treatment of infectious multiple organ dysfunction syndrome by integrated traditional Chinese and Western medicine
相关作者
暂无数据
相关机构
Department of Nephrology, Guangdong Provincial Hospital of Chinese Medicine
Department of Nephrology, 2nd Affiliated Hospital of Guangzhou University of Chinese Medicine
Institute of Nephrology, State Key Laboratory of Kidney Disease (2011DAV)00088, Chinese PLA General Hospital
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Integration of Traditional Chinese and Western Medicine, Peking University School of Oncology, Beijing Cancer Hospital and Institute
Department of Laboratory Medicine, Shenzhen Hospital Affiliated to Peking University